300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Travel
Platforms
Local
Oil and Gas
InsurTech
Retail
Film
Fitness
Payments
Marketplace
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Sports
Education
Biotechnology
Legal
Automotive
Renewable Energy
eSports
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Celebrity
Social
Food and Beverage
Life Science
Publishing
Cannabis
Wine and Spirits
Mobile Apps
Real Estate
LGBT
Sporting Goods
Music
Art
Finance
Manufacturing
Climate
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Burkina Faso
Africa
LATAM
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Armenia
Colombia
China
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Seychelles
Botswana
Paraguay
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Peru
Mongolia
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Balyasny Asset Management, VC Fund

Balyasny Asset Management

VC Fund

Chicago, United States

Balyasny Asset Management (BAM) is a diversified global investment firm founded in 2001 by Dmitry Balyasny, Scott Schroeder, and Taylor O'Malley. With over $37 billion in assets under management, BAM employs more than 2,800 people across 24 offices in the U.S. and Canada, Europe, the Middle East, and Asia. The firm’s investment teams span five strategies, including Equities Long/Short, Fixed Income & Macro, Commodities, Multi-Asset Arbitrage, and Systematic. Balyasny’s mission is to deliver to its investors absolute, uncorrelated returns in all market environments.

Total investments:
56
Last investment:
Lead investor:
9%
Fund size:
$2.5M
Last fund:

Last updated:

Industries Balyasny Asset Management invests in

BiotechnologyHealth CarePharmaceuticalBiopharmaTherapeutics

Stages Balyasny Asset Management invests in

Post-IPO EquitySeries ASeries DSeries CSeries B

Countries Balyasny Asset Management invests in

United StatesChinaLatviaSwedenBelgium

Round sizes

Series A $6.1M–$179MSeries D $35M–$225MPost-IPO Equity $35M–$197M

Contacts

NameEmailPhoneSocials
See all 10 contacts →

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$6.1M–$179M
Series D
$35M–$225M
Post-IPO Equity
$35M–$197M

Investment Focus

Industry

  • Biotechnology 28 (50%)
  • Health Care 17 (30%)
  • Pharmaceutical 12 (21%)
  • Biopharma 11 (20%)
  • Therapeutics 9 (16%)
See all 88 industries →

Stage

  • Post-IPO Equity 18 (32%)
  • Series A 8 (14%)
  • Series D 7 (13%)
  • Series C 5 (9%)
  • Series B 3 (5%)
See all 9 stages →

Country

  • United States 41 (73%)
  • China 3 (5%)
  • Latvia 1 (2%)
  • Sweden 1 (2%)
  • Belgium 1 (2%)
See all 6 countries →

Team

NameTitleInvestmentsLinksEmail
Michael Magnell
Michael Magnell Senior Analyst
Senior Analyst Total investments: 0
Find email
Brad Downes
Brad Downes Associate Director - Strategic Finance
Associate Director - Strategic Finance Total investments: 0
Find email
David Black
David Black Managing Director Business Development
Managing Director Business Development Total investments: 0
Find email
David Shaw
David Shaw Senior Analyst
Senior Analyst Total investments: 0
Find email
Douglas Cilento
Douglas Cilento Head of Macro Trading
Head of Macro Trading Total investments: 0
Find email
See all 10 team members →

Investments

CompanyDescriptionRoundLinks
Kalshi is a federally regulated financial exchange that allows investors to trade directly on the anticipated outcome of future events. Kalshi’s markets cover a wide range of topics including economics, international affairs, media and entertainment, climate/weather, and public health. Because Kalshi’s market topics can be more specific thanother instruments like stocks or bonds, investors can get direct exposure to the events and trends that they are interested in. For example, a Kalshi market on whether a certain free trade agreement will be signed can help retail investors get exposure to emerging markets and fluctuations in international trade.Website: https://kalshi.com $1B / Series G / Oct 29, 2026
Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.Since their founding in 2014, their experienced team has secured partnerships with leading global biopharma companies, generating a broadpipeline of innovative drug candidates.They see theirselves as the trusted partner of choice for global biopharmaceutical companies seeking to access the Chinese market. Leveraging their team’s extensive global drug development expertise, combined with their demonstrated understanding of the pharmaceutical industry, the increasingly favorable clinical and regulatory environment in China and their in-house manufacturing capabilities, they plan to continue to secure relationships with global pharmaceutical companies to further expand their pipeline and foster innovation in China.Their team is passionate about bringing transformative new medicines to patients. Their vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing their partner’s and their own products in China and around the world. To that end, they have built manufacturing capabilities to support the clinical and commercial production of their drug candidates in China, and they expect to have further clinical production capabilities in the near future. Their team is planning to establish a specialized commercial team to support marketing of their products in China and beyond, and they are expanding their discovery efforts both internally and through collaborations with leading academic institutions. $250M / Post-IPO Equity / Oct 22, 2026
Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology. $135M / Series B / Oct 13, 2026
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with thegoal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. $150M / Post-IPO Equity / Aug 21, 2026
Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem celltransplant. $132M / Post-IPO Equity / Jul 16, 2026
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. $75M / Series D / Jun 25, 2026
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines. $32.5M / Series A / Jun 01, 2026
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. $115M / Post-IPO Equity / May 18, 2026
Cellectar Biosciences, a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The company's product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignantcells.Cellectar Biosciences was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin. $35M / Post-IPO Equity / May 05, 2026
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics. $125M / Series A / Apr 28, 2026
See all 56 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Travel
Platforms
Local
Oil and Gas
InsurTech
Retail
Film
Fitness
Payments
Marketplace
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Sports
Education
Biotechnology
Legal
Automotive
Renewable Energy
eSports
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Celebrity
Social
Food and Beverage
Life Science
Publishing
Cannabis
Wine and Spirits
Mobile Apps
Real Estate
LGBT
Sporting Goods
Music
Art
Finance
Manufacturing
Climate
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Burkina Faso
Africa
LATAM
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Armenia
Colombia
China
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Seychelles
Botswana
Paraguay
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Peru
Mongolia
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Balyasny Asset Management invest in?

Balyasny Asset Management invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Post-IPO Equity and Series A stage. Most of the 56 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does Balyasny Asset Management invest in?

Balyasny Asset Management typically joins rounds of $6.1M–$179M at Series A, $35M–$225M at Series D and $35M–$197M at Post-IPO Equity. These are whole funding-round sizes, not Balyasny Asset Management's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Balyasny Asset Management took part in.

How do I contact Balyasny Asset Management?

Public channels for Balyasny Asset Management include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Balyasny Asset Management?

The team at Balyasny Asset Management includes Michael Magnell (Senior Analyst), Brad Downes (Associate Director - Strategic Finance) and David Black (Managing Director Business Development), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Balyasny Asset Management Balyasny Asset Management Find emails